Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.

[1]  A. Stathis,et al.  BET Proteins as Targets for Anticancer Treatment. , 2018, Cancer discovery.

[2]  G. Choi,et al.  BET Inhibitors as Anticancer Agents: A Patent Review. , 2017, Recent patents on anti-cancer drug discovery.

[3]  A. Brasier,et al.  Drug Discovery Targeting Bromodomain-Containing Protein 4 , 2017, Journal of medicinal chemistry.

[4]  Y. Taniguchi.  The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins , 2016, International journal of molecular sciences.

[5]  B. Turk,et al.  Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms , 2016, Proceedings of the National Academy of Sciences.

[6]  Yan Zhang,et al.  Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. , 2016, Journal of medicinal chemistry.

[7]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[8]  Bhairavi Tolani,et al.  Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors , 2013, Oncogene.

[9]  Andrew J. Bannister,et al.  BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms , 2014, Leukemia.

[10]  R. Prinjha,et al.  Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. , 2014, Blood.

[11]  S. Knapp,et al.  Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands , 2013, Journal of medicinal chemistry.

[12]  S. Knapp,et al.  The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. , 2013, MedChemComm.

[13]  Tony Kouzarides,et al.  Targeting epigenetic readers in cancer. , 2012, The New England journal of medicine.

[14]  David M. Wilson,et al.  Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.

[15]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[16]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[17]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[18]  H. Hellinga,et al.  Thermodynamic analysis of ligand-induced changes in protein thermal unfolding applied to high-throughput determination of ligand affinities with extrinsic fluorescent dyes. , 2010, Biochemistry.

[19]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[20]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[21]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[22]  C. Chiang,et al.  Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4 , 2009, F1000 biology reports.

[23]  Jonathan Bard,et al.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.

[24]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.